Key points are not available for this paper at this time.
Abstract Background Rituximab has greatly improved the outcomes of ABO ‐incompatible living donor liver transplantation ( ABO ‐I LDLT ). To clarify the optimal regimen for rituximab in adult ABO ‐I LDLT , a multicenter study was conducted in Japan. Methods Clinical data of 33 adult patients undergoing ABO ‐I LDLT at 15 centers in 2013 were retrospectively corrected. Results The targeted blood type was A1 in 18, B in 14, and AB in one patient. Rituximab was administered at 7 to 48 days before LT , at a dose of 375 mg/m 2 in 12 patients, 500 mg in 15 patients, 300 mg in five patients, and 100 mg in one patient. Adverse effects of rituximab were tolerable. Overall 1‐year patient survival was 81%; antibody‐mediated rejection ( AMR ) occurred in three patients (9%), two of whom died. Rituximab dose was significantly lower in patients with AMR ( P < 0.001, 137 ± 61 vs. 307 ± 66 mg/m 2 ). Among rituximab dose ( n = 28), local infusion ( n = 11), splenectomy ( n = 23), prophylactic intravenous immunoglobulins ( n = 12), preoperative tacrolimus ( n = 9), preoperative antimetabolites ( n = 21), and plasmapheresis ( n = 23), only rituximab dose was a significantly favorable factor for AMR ( P < 0.001). Conclusion The use of rituximab at sufficient doses is recommended in adult ABO ‐I LDLT .
Egawa et al. (2016) studied this question.